Takeda receives complete response letter from the u.s. fda for tak-721

Osaka, japan & cambridge, mass.--(business wire)--takeda pharmaceutical company limited (tse:4502/nyse:tak) (“takeda”) today announced that it has received a complete response letter (crl) from the u.s. food and drug administration (fda) in response to its new drug application (nda) for tak-721 (budesonide oral suspension) for the treatment of eosinophilic esophagitis (eoe), a chronic inflammatory disease of the esophagus.1 the crl indicates the fda has completed its review of the tak-721 nda a
TAK Ratings Summary
TAK Quant Ranking